Epstein Becker Green

August 15, 2011 

by Sarah K. Giesting, Amy Dow, and Daniel G. Gottlieb

On July 8, 2011, Governor Paul LePage of Maine signed into law LD 719, “An Act to Make Certain Prescription Drug Disclosure Laws Consistent with Federal Law” (“LD 719”).  LD 719 repeals three statutes that require prescription drug manufacturers and labelers to disclose information related to clinical trials, ME. REV. STAT. ANN. tit. 22, § 2700-A (“§ 2700-A”); marketing costs, ME. REV. STAT. ANN. tit. 22, § 2698-A (“§ 2698-A”); and drug pricing, ME. REV. STAT. ANN. tit. 22, § 2698-B (“§ 2698-B”).  The repeal becomes effective on September 28, 2011.  This Client Alert discusses LD 719. 

Read the full alert online

Tags:

This entry was posted by cmonfils on Tuesday, August 16th, 2011 at 10:31 am and is filed under Maine, News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.